ongoing

Recent data suggest that a thrombogenic atrial substrate can cause stroke in the absence of atrial fibrillation.

The aim of the ARCADIA trial is to determine if apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.

The ARCADIA study is managed by Mitchell S.V. Elkind, Professor of Neurology and Epidemiology at Columbia University.

Study Type

Interventional - Drug

Study Design

RCT

NO. of Countries

2

NO. of Participants

300

Study Period

2020 - 2022

Sponsor

NIH StrokeNet (through Columbia University)

NINDS

BMS/Pfizer (in-kind support)

Roche (in-kind support)

Back To Top